SMA Foundation and PTC Therapeutics Expand Partnership and Commit to an Initial Investment of Up to $60M to Advance Drug Discovery and Development Research in Regenerative Medicine

The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics have entered a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders. Recent FDA approvals of several disease modifying therapies for SMA has made regenerative medicine approaches the next frontier in drug discovery and development. The SMA Foundation-PTC Therapeutics partnership will provide funding, managed by the SMA Foundation, to academic institutions and other collaborators to advance foundational research in regenerative medicine. The SMA Foundation and PTC Therapeutics will commit to an initial investment of up to $60M in research to discover and develop promising regenerative treatments in neuromuscular diseases.

For more information, please see the press release from PTC Therapeutics.